Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 10/20 | 0.70 |
| ▸ | KDR | P35968 | 7/20 | 0.65 |
| ▸ | BRAF | P15056 | 4/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.65 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.65 |
| ▸ | SRC | P12931 | 2/20 | 0.59 |
| ▸ | CDK8 | P49336 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.53 |
| ▸ | CIT | O14578 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | MUSK | O15146 | 1/20 | 0.53 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.53 |
| ▸ | MLNR | O43193 | 1/20 | 0.53 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.53 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.53 |
| ▸ | PDE6D | O43924 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16990727 | 0.88 | RAF1 (0.60) | RAF1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL5568335 | 0.86 | KDR (0.67) | RAF1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL939171 | 0.86 | CDK8 (0.70) | RAF1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL30462521 | 0.85 | RAF1 (0.73) | RAF1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL936533 | 0.85 | RAF1 (0.73) | RAF1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL3166444 | 0.85 | KDR (0.68) | RAF1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL548328 | 0.85 | RAF1 (0.79) | RAF1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL29045853 | 0.83 | RAF1 (0.70) | RAF1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL549001 | 0.83 | RAF1 (1.00) | RAF1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL940018 | 0.81 | RAF1 (1.00) | RAF1KDRBRAFMAPK14TNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1580188-B9 | Aryl ureas as kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-23 | — | — | EP | claimed |
| US-7652022-B2 | N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; | NOVARTIS AG (CH) | 2010-01-26 | — | — | US | claimed |
| EP-1511730-B8 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2009-04-08 | — | — | EP | claimed |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | FLOERSHEIMER ANDREAS | 2006-06-15 | — | — | US | claimed |
| EP-1511730-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-09 | — | — | EP | claimed |
| WO-2003099771-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | claimed |
| US-20130338168-A1 | Combinations of JAK Inhibitors | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| EP-1580188-B9 | Aryl ureas as kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20100280003-A1 | COMBINATIONS OF JAK INHIBITORS | COOKE NIGEL GRAHAM | 2010-11-04 | — | — | US | disclosed |
| US-20090156602-A1 | Organic Compounds | COOKE NIGEL GRAHAM | 2009-06-18 | — | — | US | disclosed |
| US-20080207591-A1 | Organic Compounds | MANLEY PAUL W | 2008-08-28 | — | — | US | disclosed |
| EP-1580188-A1 | Aryl ureas as kinase inhibitors | Bayer Pharmaceuticals Corporation (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1474393-A1 | ARYL UREAS AS KINASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003068746-A1 | ARYL UREAS AS KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280003-A1 | COMBINATIONS OF JAK INHIBITORS | JAK2, JAK3, JAK1 | RAF1 30/4885KDR 123/4885BRAF 17/4885 |
| US-20130338168-A1 | Combinations of JAK Inhibitors | JAK2, JAK3, JAK1 | RAF1 30/4885KDR 123/4885BRAF 17/4885 |
| US-20080207591-A1 | Organic Compounds | FLT4, FLT1, FLT3 | RAF1 885/4885KDR 7/4885BRAF 112/4885 |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | UCK2, PRKDC, PRKACA | RAF1 171/4885KDR 3898/4885BRAF 284/4885 |
| US-20090156602-A1 | Organic Compounds | BTK, JAK2, JAK3 | RAF1 52/4885KDR 74/4885BRAF 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.